论文部分内容阅读
作者报道连续静脉内输注小剂量阿糖胞苷(LDARA-C)治疗预后差的急性非淋巴细胞白血病(ANLL)12例,其中男9例,女3例。9例年龄超过65岁(66-82岁),其中6例先前有骨髓增生异常综合征(MDS)病史,其余3例为先前经多种治疗后又复发的患者。阿糖胞苷按20mg/m~2/日,14天为1疗程。在血细胞计数最低(17-21天)时,作骨髓检查,当外周血象恢复时(28-30天)再作1次骨髓检查。获完全缓解(CR)者继续接受LDARA-C 1-2个疗程作为巩固治疗或停止治疗,获部分缓解(PR)者,再给1疗程LDARA-C或病情恶化时再治疗。结果:8/12例(67%)获CR和PR(CR5例,PR3例),7/9例老年ANLL患者获CR(4/9例)及PR(3/9例)。5/6例有
The authors report the continuous intravenous infusion of small doses of cytarabine (LDARA-C) in the treatment of poor prognosis of acute non-lymphocytic leukemia (ANLL) in 12 cases, 9 males and 3 females. Nine patients aged 65 years (66-82 years), six with previous history of myelodysplastic syndrome (MDS) and the remaining three with previously relapsed patients after multiple treatments. Cytarabine by 20mg / m ~ 2 / day, 14 days for a course of treatment. For the lowest blood cell count (17-21 days) for bone marrow examination, when the recovery of peripheral blood (28-30 days) for another bone marrow examination. Those with complete remission (CR) continue to receive 1-2 courses of LDARA-C as part of consolidation therapy or discontinuation of treatment, those with partial remission (PR), one course of LDARA-C or re-treatment if their condition deteriorates. Results: CR / PR (CR5 and PR3) were found in 8/12 cases (67%) and CR (4/9 cases) and PR (3/9 cases) in 7 of 9 elderly ANLL patients. 5/6 cases there